ARCHIVES

GA101 Associated with Better PFS In Phase III Trial Versus Rituximab in CLL

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Dose Dense Chemotherapy Regimen Improves Survival In Breast Cancer

December 27, 2002

ODAC Rejects Amsacrine NDA, Renews Idarubicin

September 14, 1990

FDA Told To Drop Guidelines, But Remains Unmoved On New Drug Delays

December 5, 1975

NCAB Ponders Patient Accrual Problems, Members Irate Over System That Discourages Participation

February 19, 1988

NCI Advisors Approve Recompetition Of $132 Million Proteomic Technologies Network

March 12, 2010

At Least 25 CCOP Applicants Score High Enough To Virtually Assure Funding; Geography An Issue

May 13, 1983